MCM
CYCN icon

MV Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

MV Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3
Closed -$23 – 684
2023
Q1 		$23 Buy
+3
New +$38 ﹤0.01% 694

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MV Capital Management's CYCN Position: Q2 2023 in Review

MV Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 3 shares — an estimated $23 sold.

MV Capital Management first reported a position in CYCN in Q1 2023 and held it in 1 quarter. The position peaked at $23 in Q1 2023. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

  • MV Capital Management reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • MV Capital Management sold 3 Cyclerion Therapeutics shares in Q2 2023, an estimated $23.
  • MV Capital Management first reported a position in Cyclerion Therapeutics in Q1 2023 and held it in 1 quarter.
  • MV Capital Management's Cyclerion Therapeutics position peaked at $23 in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on MV Capital Management's 13F filing for Q2 2023, filed 3 Aug 2023.